Ashling Wahner

Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.

Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.

The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.

Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.

Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.

A phase 2 trial of stenoparib in advanced recurrent ovarian cancer has been closed early to enable a follow-on trial with FDA regulatory intent.

Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.

Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.

The investigational therapy IGNK001 has received orphan drug designation from the FDA for patients with acute myeloid leukemia.

Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.

HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.

Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.

The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.

Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.

Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.

Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

BVX001 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.

Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.

Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.

Shirish M, Gadgeel, MD, highlights key treatment advances achieved with antibody-drug conjugates in non–small cell lung cancer.

Updated phase 1 findings with botensilimab/balstilimab in MSS/pMMR mCRC show that the regimen elicited respective 12- and 18-month OS rates of 71% and 62%.

Tamibarotene plus azacitidine and venetoclax has received FDA fast track designation for newly diagnosed, unfit, RARA-overexpressed AML.

Stereotactic ablative body radiotherapy elicited high local control rates in patients with renal cell carcinoma who did not undergo surgical resection.

The European Commission has expanded its approval of luspatercept to include frontline treatment of transfusion-dependent anemia due to lower-risk MDS.

The FDA has approved danicopan as add-on therapy to ravulizumab or eculizumab for extravascular hemolysis in paroxysmal nocturnal hemoglobinuria.